



TEXAS
Health and Human
Services

**Texas Department of State
Health Services**

Dear Texas Vaccines for Children and Adult Safety Net (TVFC/ASN) Provider,

On June 3, 2022, [the Food and Drug Administration \(FDA\)](#) approved a live attenuated vaccine by GlaxoSmithKline (GSK) Biologicals SA, Priorix®, for active immunization for the prevention of measles, mumps, and rubella (MMR) in individuals 12 months of age and older. Priorix® underwent review by the Centers for Disease Control and Prevention (CDC) [Advisory Committee on Immunization Practices \(ACIP\)](#) on June 22, 2022, and was recommended to be offered as an additional vaccine choice to prevent MMR.

The Texas Department of State Health Services (DSHS) Immunization Program will be hosting a webinar on November 29th, 2022, at 10:00AM CST at the following link:

<https://attendee.gotowebinar.com/register/5898522968859621136>

The vaccine manufacturer GSK will be discussing vaccine safety and efficacy, clinical recommendations, and be available to answer any questions.

[Priorix®](#) will be available for ordering through the federal adult and pediatric contracts and will be available for providers to order in the Vaccine Allocation and Ordering System (VAOS) under the Texas Vaccines for Children (TVFC) and Adult Safety Net Program(s) on December 1, 2022.

GSK recommendations on the vaccine can be found [here](#).

For additional questions regarding the Priorix® vaccine, contact your Responsible Entity (RE).

Thank you for your continued participation,

Texas Department of State Health Services
Immunization Program